Advertisement

Acquired Demyelinating Diseases

  • Àlex Rovira
  • Kelly K. KoellerEmail author
Chapter

Abstract

Demyelinating disorders of the central nervous system (CNS) have a variety of etiologies and can be separated into primary (e.g., multiple sclerosis (MS) and other idiopathic inflammatory-demyelinating diseases) and secondary (e.g., infectious, ischemic, metabolic, or toxic) diseases. Brain and spinal cord magnetic resonance imaging (MRI) is the imaging modality of choice to assess demyelinating disorders and, together with the clinical and laboratory findings, can accurately classify them in most cases [1–3]. This review will highlight the important imaging manifestations of some acquired demyelinating diseases that allow more specific diagnosis.

Keywords

Demyelinating diseases White matter Brain Multiple sclerosis Metabolic diseases Ischemia Radiotherapy Chemotherapy MR imaging NMO ADEM Diagnosis Acquired 

References

  1. 1.
    Smith AB, Smirniotopoulos JG (2010) Imaging evaluation of demyelinating processes of the central nervous system. Postgrad Med J 86:218–229CrossRefPubMedGoogle Scholar
  2. 2.
    Cañellas AR, Gols AR, Izquierdo JR et al (2007) Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology 49:393–409CrossRefPubMedGoogle Scholar
  3. 3.
    Aliaga ES, Barkhof F (2014) MRI mimics of multiple sclerosis. Handb Clin Neurol 122:291–316CrossRefPubMedGoogle Scholar
  4. 4.
    Rovira A, León A (2008) MR in the diagnosis and monitoring of multiple sclerosis: an overview. Eur J Radiol 67:409–414CrossRefPubMedGoogle Scholar
  5. 5.
    Filippi M, Rocca MA (2011) MR imaging of multiple sclerosis. Radiology 259:659–681CrossRefPubMedGoogle Scholar
  6. 6.
    Rovira À, Wattjes MP, Tintoré M et al (2015) Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 11:471–482CrossRefPubMedGoogle Scholar
  7. 7.
    Bagnato F, Jeffries N, Richert ND et al (2003) Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 126:1782–1789CrossRefPubMedGoogle Scholar
  8. 8.
    Lycklama G, Thompson A, Filippi M et al (2003) Spinal-cord MRI in multiple sclerosis. Lancet Neurol 2:555–562CrossRefPubMedGoogle Scholar
  9. 9.
    Cotton F, Weiner HL, Jolesz FA et al (2003) MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 60:640–646CrossRefPubMedGoogle Scholar
  10. 10.
    Masdeu JC, Quinto C, Olivera C et al (2000) Open-ring imaging sign: highly specific for atypical brain demyelination. Neurology 54:1427–1433CrossRefPubMedGoogle Scholar
  11. 11.
    Popescu BF, Lucchinetti CF (2012) Pathology of demyelinating diseases. Annu Rev Pathol 7:185–217CrossRefPubMedGoogle Scholar
  12. 12.
    Mehler MF, Rabinowich L (1989) Inflammatory myelinoclastic diffuse sclerosis (Schilder’s disease): neuroradiologic findings. AJNR Am J Neuroradiol 10:176–180PubMedGoogle Scholar
  13. 13.
    Hardy TA, Miller DH (2014) Baló’s concentric sclerosis. Lancet Neurol 13:740–746CrossRefPubMedGoogle Scholar
  14. 14.
    Stadelmann C, Ludwin S, Tabira T et al (2005) Tissue preconditioning may explain concentric lesions in Baló’s type of multiple sclerosis. Brain 128:979–987CrossRefPubMedGoogle Scholar
  15. 15.
    Trebst C, Jarius S, Berthele A et al (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261:1–16CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112CrossRefPubMedGoogle Scholar
  17. 17.
    Wingerchuk DM, Lennon VA, Pittock SJ et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489CrossRefPubMedGoogle Scholar
  18. 18.
    Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Yonezu T, Ito S, Mori M et al (2014) “Bright spotty lesions” on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler 20:331–337CrossRefPubMedGoogle Scholar
  20. 20.
    Kim HJ, Paul F, Lana-Peixoto MA et al (2015) MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 84:1165–1173CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Misu T, Fujihara K, Nakashima I et al (2005) Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 65:1479–1482CrossRefPubMedGoogle Scholar
  22. 22.
    Krupp LB, Tardieu M, Amato MP et al (2013) International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 19:1261–1267CrossRefPubMedGoogle Scholar
  23. 23.
    Verhey LH, Branson HM, Shroff MM et al (2011) MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol 10:1065–1073CrossRefPubMedGoogle Scholar
  24. 24.
    Tenembaum S, Chamoles N, Fejerman N (2002) Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 59:1224–1231CrossRefPubMedGoogle Scholar
  25. 25.
    Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9:425–437CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wattjes MP, Barkhof F (2014) Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. Curr Opin Neurol 27:260–270CrossRefPubMedGoogle Scholar
  27. 27.
    Gottumukkala RV, Romero JM, Riascos RF et al (2014) Imaging of the brain in patients with human immunodeficiency virus infection. Top Magn Reson Imaging 23:275–291CrossRefPubMedGoogle Scholar
  28. 28.
    Geibprasert S, Gallucci M, Krings T (2010) Alcohol-induced changes in the brain as assessed by MRI and CT. Eur Radiol 20:1492–1501CrossRefPubMedGoogle Scholar
  29. 29.
    Rovira A, Alonso J, Cordoba J (2008) MR imaging findings in hepatic encephalopathy. AJNR Am J Neuroradiol 29:1612–1621CrossRefPubMedGoogle Scholar
  30. 30.
    Arbelaez A, Pajon A, Castillo M (2003) Acute Marchiafava-Bignami disease: MR findings in two patients. AJNR Am J Neuroradiol 24:1955–1957PubMedGoogle Scholar
  31. 31.
    Gallucci M, Bozzao A, Splendiani A et al (1990) Wernicke encephalopathy: MR findings in five patients. AJR Am J Roentgenol 155:1309–1314CrossRefPubMedGoogle Scholar
  32. 32.
    Zuccoli G, Santa Cruz D, Bertolini M et al (2009) MR imaging findings in 56 patients with Wernicke encephalopathy: nonalcoholics may differ from alcoholics. AJNR Am J Neuroradiol 30:171–176CrossRefPubMedGoogle Scholar
  33. 33.
    Ruzek KA, Campeau NG, Miller GM (2004) Early diagnosis of central pontine myelinolysis with diffusion-weighted imaging. AJNR Am J Neuroradiol 25:210–213PubMedGoogle Scholar
  34. 34.
    Soussain C, Ricard D, Fike JR et al (2009) CNS complications of radiotherapy and chemotherapy. Lancet 374:1639–1651CrossRefPubMedGoogle Scholar
  35. 35.
    Cha S (2006) Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 27:475–487PubMedGoogle Scholar
  36. 36.
    Rimkus Cde M, Andrade CS, Leite Cda C et al (2014) Toxic leukoencephalopathies, including drug, medication, environmental, and radiation-induced encephalopathic syndromes. Semin Ultrasound CT MR 35:97–117CrossRefPubMedGoogle Scholar
  37. 37.
    Baehring JM, Fulbright RK (2008) Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients. J Neurol Neurosurg Psychiatry 79:535–539CrossRefPubMedGoogle Scholar
  38. 38.
    Davis P, Hoffman JJ, Pearl G et al (1986) CT evaluation of effects of cranial radiation therapy in children. AJR Am J Roentgenol 147:587–592CrossRefPubMedGoogle Scholar
  39. 39.
    Wijdicks EF, Campeau N, Sundt T (2008) Reversible unilateral brain edema presenting with major neurologic deficit after valve repair. Ann Thorac Surg 86:634–637CrossRefPubMedGoogle Scholar
  40. 40.
    McKinney AM, Short J, Truwit CL et al (2007) Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 189:904–912CrossRefPubMedGoogle Scholar
  41. 41.
    Casey SO, Sampaio RC, Michel E, Truwit CL (2000) Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol 21:1199–1206PubMedGoogle Scholar
  42. 42.
    Covarrubias D, Luetmer P, Campeau N (2002) Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol 23:1038–1048PubMedGoogle Scholar
  43. 43.
    Post JD, Beauchamp NJ (1998) Reversible intracerebral pathologic entities mediated by vascular autoregulatory dysfunction. Radiographics 18:353–367CrossRefGoogle Scholar
  44. 44.
    Kloppenborg RP, Nederkoorn PJ, Geerlings MI, van den Berg E (2014) Presence and progression of white matter hyperintensities and cognition: a meta-analysis. Neurology 82:2127–2138CrossRefPubMedGoogle Scholar
  45. 45.
    van dem Boom R, Lesnick Oberstein S et al (2006) Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: MR imaging changes and apolipoprotein E genotype. AJNR Am J Neuroradiol 27:359–362PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Section of Neuroradiology and MR Unit (IDI), Department of RadiologyHospital Universitari Vall d’Hebron, Autonomous University of BarcelonaBarcelonaSpain
  2. 2.Section of Neuroradiology, Department of RadiologyMayo ClinicRochesterUSA

Personalised recommendations